LRMR missed EPS expectations by 7.83%
May 15, 2025, 10:35 PM
0.00%
What does LRMR do
Larimar Therapeutics, based in Bala Cynwyd, Pennsylvania, focuses on developing novel therapeutics for mitochondrial disorders and Friedreich's ataxia using its cell penetrating peptide technology. Its lead candidate, nomlabofusp, aims to deliver essential protein frataxin to mitochondria for treating this rare disease.
Larimar Therapeutics (LRMR) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Larimar Therapeutics's actual EPS was -$0.46, missing the estimate of -$0.43 per share, resulting in a -7.83% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.